Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Expert Opinion on Drug Discovery|March 15, 2013
Evolving '-omics' technologies in the drug development processSandra Kraljevic Pavelic, Nina SabanMethods in Molecular Biology (Clifton, N.J.)|July 24, 2012
Using functional genomics to identify drug targets: a Dupuytren's disease exampleMirela Sedic, Sandra Kraljevic Pavelic, Karlo HockJournal of Functional Biomaterials|October 25, 2024
PMA-Zeolite: Chemistry and Diverse Medical ApplicationsAleksandar Bulog, Kresimir Pavelic, Ivana Šutić, et al.Molecular Cancer|February 24, 2011
Metastasis: new perspectives on an old problemSandra Kraljevic Pavelic, Mirela Sedic, Hrvojka Bosnjak, et al.Frontiers in Bioscience (Landmark Edition)|December 29, 2009
Functional genomics in identification of drug targets in Dupuytren's contractureMirela Sedic, Davor Jurisic, Zdenko Stanec, et al.Functional & Integrative Genomics|February 5, 2010
Integrated gene networks in breast cancer developmentIvana Ratkaj, Emil Stajduhar, Srdan Vucinic, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 18, 2008
Screening of potential prodrugs on cells derived from Dupuytren's disease patientsSandra Kraljevic Pavelic, Sinisa Bratulic, Karlo Hock, et al.Molecular Cancer Therapeutics|July 23, 2008
Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 statusMirela Sedic, Miroslav Poznic, Peter Gehrig, et al.The Journal of Pathology|December 18, 2008
An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's diseaseSandra Kraljevic Pavelic, Mirela Sedic, Karlo Hock, et al.Electrophoresis|July 7, 2011
Plasma biomarker identification in S-adenosylhomocysteine hydrolase deficiencyMirela Sedic, Sandra Kraljevic Pavelic, Mario Cindric, et al.Pageof 2